Optical coherence tomography in the preoperative and postoperative management of macular hole and epiretinal membrane

Roger A Goldberg, Nadia K Waheed, Jay S Duker

ABSTRACT
Optical coherence tomography (OCT) imaging plays an essential role in the diagnosis and treatment of macular diseases, including those of the vitreomacular interface. OCT enables accurate diagnosis and differentiation of full thickness macular hole, lamellar macular hole and epiretinal membrane, with or without the presence of vitreomacular adhesion. This information enables earlier diagnosis and treatment when necessary, and can guide the choice of therapy. OCT is useful to facilitate discussions with patients and manage the visual expectations. Postoperatively, OCT can be helpful to optimise patient comfort and visual outcomes. As the technology continues to improve, OCT will become increasingly critical for all aspects of care for patients with macular hole and epiretinal membrane.

Since Puliafito et al first described optical coherence tomography (OCT) imaging of the macula in 1995, OCT has evolved to become the gold standard for the diagnosis, management and follow-up of many vitreoretinal diseases. OCT-guided treatment for chronic conditions like age-related macular degeneration and macular oedema has become a de facto standard of care. Similarly, OCT has an increasingly important role in the management of diseases of the vitreomacular interface (VMI)—including full thickness macular hole (FTMH), lamellar macular hole (LMH), epiretinal membrane (ERM), and vitreomacular traction (VMT). A new classification system for diseases of the VMI relying entirely on OCT data to classify FTMH subtypes, supplements the pre-OCT Gass staging system.

OCT allows for accurate diagnosis and differentiation early in the disease course and assists in preoperative decision making and planning. Similarly, OCT’s role in postoperative management also helps optimise visual outcomes. This paper reviews the role of OCT in the preoperative and postoperative management of patients with FTMH and ERM.

PREOPERATIVE OCT
Diagnostic utility
Even when clinically apparent at the slit lamp, obtaining an OCT image at the time of diagnosis in patients with FTMH or ERM helps in staging, surgical planning and prognostication of anatomical and visual success. First, the OCT can confirm the diagnosis. For example, a FTMH must be distinguished from entities that can cause macular pseudohole, such as ERM, VMT or LMH. Patients with pseudoholes often retain good vision without risk of progressive photoreceptor damage, and can be more safely observed. OCT is now considered the gold standard for diagnostic confirmation of FTMH, surpassing clinical tests such as the Watzke-Allen slit beam test, in accuracy. Similarly, in evaluating for ERM and VMT, OCT has been demonstrated to be superior to clinical exam. In a prospective study, Do et al asked six vitreoretinal specialists to examine patients with slit lamp biomicroscopy and determine whether ERM or VMT was present, and to make a determination as to whether surgery was indicated. These patients then received a time domain (TD) OCT (Stratus, Zeiss). The TD OCT was found to be more sensitive than clinical exam overall, and particularly for VMT cases. OCT was also able to more consistently detect the presence of macular oedema, which has been corroborated in other diseases.

Prognostic indicators
In addition to confirming the diagnosis, OCT can be helpful in discussions with patients and their families about the disease, treatment options and visual potential after successful macular hole (MH) or ERM surgery. In patients with MH, OCT can be used to accurately measure the size of the hole, which is done by using the calliper function found on most spectral domain (SD) OCT platforms to draw a horizontal line connecting the two closest components of the retina (minimum linear dimension; figure 1). Other measurements such as the base diameter, macular hole inner opening, as well as derived measurements such as the macular hole index, have also been studied. The minimum linear dimension is a critical factor in determining the anatomical success rate of hole closure after surgery, and forms the basis for the new international OCT-based classification system for macular holes.

Similarly, in patients with ERM, the integrity of the photoreceptor inner segment/outer segment (IS/OS) junction line has proven to be an important indicator of postoperative visual acuity (figure 2). Using TD OCT (Stratus), Suh et al found that eyes with disruption of IS/OS junction had significantly lower postoperative best corrected visual acuity (BCVA) and BCVA differences between before and after surgery than those without disruption on preoperative OCT. Falkner-Radler et al performed a similar study using TD OCT and SD OCT, and confirmed that baseline IS/OS integrity was helpful to predict the functional outcomes after surgery. They noted that SD OCT allowed...
guide decision-making. In the pivotal studies, one injection of ocriplasmin was able to close 40% of FTMHs smaller than 400 microns in diameter, compared with 10.6% of placebo-injected eyes.\textsuperscript{14} In FTMHs smaller than 250 microns, the anatomical closure rate with ocriplasmin was 58%. However, in the presence of co-existent ERM, fewer than 10% of patients had resolution of their vitreomacular adhesion. Thus ocriplasmin may be a viable alternative to surgery in small and medium sized holes with persistent VMT but no ERM on OCT.

In patients who do require surgery, the risks and benefits of peeling the ILM is debated among vitreoretinal specialists in ERM and FTMH cases. In FTMH cases, studies suggest that ILM removal may improve the success rate of hole closure. However, holes smaller than 400 microns in diameter have an equivalently high rate of closure (over 90%) whether ILM is peeled or not. This finding that 400 micron aperture size was important for anatomical success rate was corroborated by the ocriplasmin data, as ocriplasmin cleaves laminin and fibronectin at the vitreoretinal interface, but does not impact the ILM.

In patients with ERM, some surgeons advocate peeling ILM to prevent ERM recurrence. Some studies suggest a recurrence rate as high as 50% when the ILM is left in place, whereas the recurrence rate of ERM is <10% when the ILM is removed.\textsuperscript{15} The ILM may serve as a platform for residual glial cells, hyalocytes and myofibroblasts to proliferate and re-form another ERM. Despite this, concern has arisen regarding the effect of ILM peeling on visual acuity, contrast sensitivity and the creation of microscotomas.\textsuperscript{17} In a single-surgeon study comparing patients who underwent ERM peel alone versus those that underwent ERM plus ILM peel, Chang et al. found that there was no difference in the postoperative visual acuity, despite a greater proportion in the ERM peel only group having residual ERM present.\textsuperscript{18} Sometimes, regardless of the surgeon’s intent preoperatively, the ILM comes off with the ERM simultaneously. Seidel et al. examined what factors on preoperative SD OCT were predictive of residual ILM after ERM peel.\textsuperscript{20} Residual ILM was determined intraoperatively by using ICG staining after the ERM peel. They found that persistent ILM was present in 50% of cases. Not surprisingly, they found that the factors most predictive of ILM persistence after ERM peel were a greater extent of ERM elevation (a looser connection between the ERM and the retinal surface) and thicker ERMs. This may help surgeons determine beforehand which patients may warrant a second staining with ICG.

Often, the most challenging aspect of membrane peeling is initiating the flap edge. Preoperative OCT can help guide surgeons where best to initiate the membrane peel. Areas on the preoperative OCT where the ERM is elevated above the retina are easier to initiate a peel, whereas membranes with closer adherence to the retinal surface are more difficult to separate from the underlying retina (figure 2).\textsuperscript{21} Similarly, OCT can be used to determine the thickest part of the membrane, as well as an identifiable edge of the membrane.\textsuperscript{22}

**POSTOPERATIVE OCT**

**Guiding prone positioning**

Vitreoretinal surgeons often debate to what extent—if at all—prone positioning is needed postoperatively to maximise the rate the of hole closure after FTMH surgery. Anatomical success rates of >90% are now routinely reported in surgical series of FTMH, leading some to question the value of face-down positioning. Several groups have demonstrated that obtaining OCT scans through gas-filled eyes is feasible, though
scan quality can vary considerably. This requires the use of an OCT system using the macular cube scan feature to ensure that B scans through the fovea are obtained. These scans enable OCT-guided positioning postoperatively.

In a study by Shah et al., 32 eyes underwent FTMH repair. Patients were instructed to maintain a facedown position overnight, and every patient received an OCT scan on postoperative day 1. If the OCT demonstrated a closed hole, patients were instructed to remain facedown for two additional days. If the hole was open or indeterminate, they were instructed to remain facedown for 1 week. Three-quarters of eyes had closed holes on postoperative day 1, and of these, 96% remained closed. Of the eight eyes with open or indeterminate holes on day 1, all were >400 microns in diameter preoperatively, and six had closed by postoperative week 1. Using this algorithm of OCT-guided prone positioning, the authors achieved an overall single-procedure closure rate of 90.6%.

Similarly, Masuyama et al. followed patients daily with postoperative OCT. As soon as the hole was closed on OCT, prone positioning was stopped. With this algorithm, 16 of 16 FTMHs closed by postoperative month 1. The authors suggest that as soon as the hole is closed on OCT, prone positioning is no longer needed. Of course, these studies do not address whether facedown positioning is necessary at all, but offer the opportunity for surgeons who do recommend prone posturing to tailor their recommendations based on OCT evidence.

Explaining visual outcomes
Postoperative OCT can also be helpful in determining why some patients have poor visual outcomes despite successful surgery. For example, OCT can easily detect subretinal or intraretinal fluid that can develop after macular surgery (figure 3). OCT can help identify this fluid, and help monitor response to therapy. Treatment options for postoperative cystoid macular oedema include topical non-steroidal anti-inflammatory drugs and corticosteroids, sub-Tenon’s or intravitreal steroids or a dexamethasone intravitreal implant.

Additionally, disruptions to the retinal pigment epithelium and photoreceptors can correlate with visual outcomes. Dissociated nerve fibre layer, recurrent ERM, and photoreceptor and retinal pigment epithelium disruptions have all been reported after surgery for FTMH and ERM.

At this point, it is not clear if one single parameter or time point on SD OCT correlates best with visual acuity. Itoh et al. reviewed 51 patients with surgically closed macular holes, and correlated the length of the foveal cone outer segment tips (COST) as measured by SD OCT with the best-corrected visual acuity at postoperative months 1, 3, 6, 9 and 12. They found that the length of the COST line defect correlated significantly with BCVA at all time points, and that the COST line defect was gradually restored in a centripetal fashion during the postoperative period.

A similar study by Kao et al. examining 77 eyes with closed macular holes found that an intact external limiting membrane at postoperative month 1 after surgery correlated best with visual outcome, regardless of the photoreceptor IS/OS status at that time. In contrast, Oh et al. found in 23 patients after macular hole surgery that poorer postoperative vision did correlate with the size of the IS/OS defect, as measured by linear (raster) and composite (partial fundus image) scans.

FUTURE DIRECTIONS

New software updates to SD OCT systems now enable en face imaging of the retinal surface. Rispoli et al. examined 20 consecutive patients with idiopathic ERMs using en face OCT imaging, and identified areas of small craters and pits adjacent to the plaque membrane. They hypothesised that membrane contraction caused localised tearing and folding of the ILM, exposing the bare retinal fibre layer underneath. These would not be good places to initiate membrane peel during surgery. Postoperatively, the authors identified areas of dimpling on en face imaging that they speculate are consistent with previously described reports of dissociated optic nerve fibre layer, though they suggest that they may be Muller cells regenerating their end feet. How en face imaging may be useful is yet to be determined.

Intraoperative OCT offers another exciting aid to the vitreoretinal surgeon during FTMH and ERM surgeries. Though no real-time, integrated system yet exists to provide the surgeon with live feedback of the precise layers being grasped, active research in this area is being pursued. Finally, swept source (SS) OCT imaging may further add to our understanding of MH and ERM pathophysiology and surgical outcomes. SS OCT can image at speeds of 100 000–400 000 axial scans per second with a 1050 nm light source, enabling wide-field imaging, improved deep choroidal imaging and faster acquisition speeds. What role SS OCT will play for patients with ERM and MH is yet to be determined.

CONCLUSION
OCT has revolutionised all facets of our management of patients with FTMH and ERM. Over the past decade, OCT has become an essential component of the preoperative evaluation of FTMH and ERM, confirming the diagnosis, aiding in surgical planning and explaining visually to patients what these diagnoses mean. Similarly, postoperatively, OCT can help predict and explain the visual outcome, guide therapeutic decision-making such as prone positioning or the need for—and response to—treatment for cystoid macular oedema. New advances currently in development will likely expand the role of OCT even further, for the benefit of our patients with FTMH and ERM.

Contributors All authors contributed to the (1) conception and design of this manuscript, (2) its drafting and revisions, and (3) its final approval.

Competing interests JSD receives research support from Carl Zeiss Meditech and Optovue.

Provenance and peer review Not commissioned; externally peer reviewed.

Open Access This is an Open Access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 3.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially,
REFERENCES

4. Tanner V, Williamson TH. Watzke-Allen slit beam test in macular holes con... 
Optical coherence tomography in the preoperative and postoperative management of macular hole and epiretinal membrane

Roger A Goldberg, Nadia K Waheed and Jay S Duker

*Br J Ophthalmol* 2014 98: ii20-ii23 originally published online March 13, 2014
doi: 10.1136/bjophthalmol-2013-304447

Updated information and services can be found at:
http://bjo.bmj.com/content/98/Suppl_2/ii20

These include:

**References**
This article cites 35 articles, 3 of which you can access for free at:
http://bjo.bmj.com/content/98/Suppl_2/ii20#BIBL

**Open Access**
This is an Open Access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 3.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/3.0/

**Email alerting service**
Receive free email alerts when new articles cite this article. Sign up in the box at the top right corner of the online article.

**Topic Collections**
Articles on similar topics can be found in the following collections

- Open access (271)
- Retina (1608)
- Macula (27)

**Notes**

To request permissions go to:
http://group.bmj.com/group/rights-licensing/permissions

To order reprints go to:
http://journals.bmj.com/cgi/reprintform

To subscribe to BMJ go to:
http://group.bmj.com/subscribe/